Home LiteratureArticle Details
PMID: 17222480 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Hippocampal hypometabolism predicts cognitive decline from normal aging.

Neurobiology of aging ·Vol. 29 ·No. 5 ·2008-05-00 ·Pages 676-92

Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ

Abstract

This longitudinal study used FDG-PET imaging to predict and monitor cognitive decline from normal aging. Seventy-seven 50-80-year-old normal (NL) elderly received longitudinal clinical examinations over 6-14 years (561 person-years, mean per person 7.2 years). All subjects had a baseline FDG-PET scan and 55 subjects received follow-up PET exams. Glucose metabolic rates (MRglc) in the hippocampus and cortical regions were examined as predictors and correlates of clinical decline. Eleven NL subjects developed dementia, including six with Alzheimer's disease (AD), and 19 declined to mild cognitive impairment (MCI), on average 8 years after the baseline exam. The baseline hippocampal MRglc predicted decline from NL to AD (81% accuracy), including two post-mortem confirmed cases, from NL to other dementias (77% accuracy), and from NL to MCI (71% accuracy). Greater rates of hippocampal and cortical MRglc reductions were found in the declining as compared to the non-declining NL. Hippocampal MRglc reductions using FDG-PET during normal aging predict cognitive decline years in advance of the clinical diagnosis. Future studies are needed to increase preclinical specificity in differentiating dementing disorders.

MeSH Terms
Aged Aged, 80 and over Aging/metabolism Cognition Disorders/complications,diagnostic imaging,metabolism Dementia/diagnostic imaging,metabolism Female Fluorodeoxyglucose F18/pharmacokinetics Glucose/metabolism Glucose Metabolism Disorders/complications,diagnostic imaging,metabolism Hippocampus/diagnostic imaging,metabolism Humans Male Middle Aged Radionuclide Imaging Radiopharmaceuticals/pharmacokinetics Statistics as Topic
Chemicals
Radiopharmaceuticals Fluorodeoxyglucose F18 Glucose
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Mosconi Lisa
New York University School of Medicine, New York, NY 10016, USA.
De Santi Susan
Li Juan
Tsui Wai Hon
Li Yi
Boppana Madhu
Laska Eugene
Rusinek Henry
de Leon Mony J
References (50)
50 references, click to expand
  1. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
    Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13 PMID: 12764551
  2. Mild cognitive impairment.
    Lancet. 2006 Apr 15;367(9518):1262-70 PMID: 16631882
  3. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging.
    Radiology. 2003 Dec;229(3):691-6 PMID: 14657306
  4. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.
    Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9 PMID: 14688411
  5. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
    Neurology. 2004 Feb 24;62(4):591-600 PMID: 14981176
  6. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  7. Advances in the early detection of Alzheimer's disease.
    Nat Med. 2004 Jul;10 Suppl:S34-41 PMID: 15298007
  8. Multi-infarct dementia. A cause of mental deterioration in the elderly.
    Lancet. 1974 Jul 27;2(7874):207-10 PMID: 4135618
  9. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.
    J Neurochem. 1977 May;28(5):897-916 PMID: 864466
  10. The Global Deterioration Scale for assessment of primary degenerative dementia.
    Am J Psychiatry. 1982 Sep;139(9):1136-9 PMID: 7114305
  11. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  12. A new definition of Alzheimer's disease: a hippocampal dementia.
    Lancet. 1985 Jan 5;1(8419):14-6 PMID: 2856948
  13. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose.
    J Cereb Blood Flow Metab. 1985 Jun;5(2):179-92 PMID: 3988820
  14. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease.
    Neurology. 1989 Nov;39(11):1537-9 PMID: 2812339
  15. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type.
    Arch Neurol. 1990 Jul;47(7):753-60 PMID: 2357155
  16. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging.
    J Comput Assist Tomogr. 1990 Jul-Aug;14(4):561-70 PMID: 2370355
  17. Neuropathological stageing of Alzheimer-related changes.
    Acta Neuropathol. 1991;82(4):239-59 PMID: 1759558
  18. Brain tissue volume measurement from magnetic resonance imaging. A phantom study.
    Invest Radiol. 1993 Oct;28(10):890-5 PMID: 8262742
  19. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.
    JAMA. 1995 Mar 22-29;273(12):942-7 PMID: 7884953
  20. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.
    J Comput Assist Tomogr. 1995 Jul-Aug;19(4):541-7 PMID: 7622680
  21. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease.
    Neurology. 1996 Aug;47(2):462-6 PMID: 8757021
  22. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.
    J Nucl Med. 1997 May;38(5):797-802 PMID: 9170449
  23. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.
    Ann Neurol. 1997 Jul;42(1):85-94 PMID: 9225689
  24. Life and death of neurons in the aging brain.
    Science. 1997 Oct 17;278(5337):412-9 PMID: 9334292
  25. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease.
    Neurology. 1998 Jun;50(6):1585-93 PMID: 9633698
  26. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease.
    J Psychiatr Res. 1999 Jan-Feb;33(1):7-16 PMID: 10094234
  27. Mild cognitive impairment: clinical characterization and outcome.
    Arch Neurol. 1999 Mar;56(3):303-8 PMID: 10190820
  28. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition.
    Am J Psychiatry. 1999 Apr;156(4):531-7 PMID: 10200730
  29. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease.
    Lancet. 1999 Jun 19;353(9170):2125 PMID: 10382699
  30. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
    Nature. 1999 Jul 8;400(6740):173-7 PMID: 10408445
  31. Mixed-effects and fMRI studies.
    Neuroimage. 2005 Jan 1;24(1):244-52 PMID: 15588616
  32. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
    Neurology. 2004 Dec 28;63(12):2332-40 PMID: 15623696
  33. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
    Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510 PMID: 15747152
  34. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.
    Neurology. 2005 Jun 14;64(11):1860-7 PMID: 15955934
  35. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
    J Nucl Med. 2005 Oct;46(10):1625-32 PMID: 16204712
  36. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles.
    Neuron. 1999 Nov;24(3):521-9 PMID: 10595506
  37. Are memory complaints predictive for dementia? A review of clinical and population-based studies.
    Int J Geriatr Psychiatry. 2000 Nov;15(11):983-91 PMID: 11113976
  38. Hippocampal formation glucose metabolism and volume losses in MCI and AD.
    Neurobiol Aging. 2001 Jul-Aug;22(4):529-39 PMID: 11445252
  39. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.
    Lancet. 2001 Jul 21;358(9277):201-5 PMID: 11476837
  40. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  41. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  42. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.
    Nat Med. 2003 Apr;9(4):448-52 PMID: 12640446
  43. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
    Neurology. 2003 Apr 22;60(8):1374-7 PMID: 12707450
  44. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.
    Neurobiol Aging. 2003 Jul-Aug;24(4):521-36 PMID: 12714109
  45. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.
    Neuroimage. 2003 Jul;19(3):1233-9 PMID: 12880848
  46. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease.
    Arch Neurol. 2005 Nov;62(11):1728-33 PMID: 16286547
  47. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people.
    Arch Gen Psychiatry. 2006 Jan;63(1):57-62 PMID: 16389197
  48. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.
    Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):210-21 PMID: 16311757
  49. Memory complaint is not necessary for diagnosis of mild cognitive impairment and does not predict 10-year trajectories of functional disability, word recall, or short portable mental status questionnaire limitations.
    J Am Geriatr Soc. 2006 Feb;54(2):335-8 PMID: 16460388
  50. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment.
    Ann Neurol. 2003 Sep;54(3):343-51 PMID: 12953266
Article Info
Journal
Neurobiology of aging
Abbr.
Neurobiol Aging
ISSN
1558-1497
DOI
10.1016/j.neurobiolaging.2006.12.008
Published
2008-05-00
Epub
2007-00-11
Pages
676-92
Language
English
Region
United States
NLM ID
8100437
PMCID
PMC2430185
Subset
IM
Grants
NIA NIH HHS · R01 AG022374 · United States
NCRR NIH HHS · M01 RR000096 · United States
NCRR NIH HHS · MO1RR0096 · United States
NIA NIH HHS · R01 AG013616 · United States
NCRR NIH HHS · M01 RR000096-46 · United States
NIA NIH HHS · P30 AG008051 · United States
NIA NIH HHS · R01 AG012101 · United States
NIA NIH HHS · R01 AG013616-17 · United States
NIA NIH HHS · AG022374 · United States
NIA NIH HHS · P30 AG008051-18 · United States
NIA NIH HHS · R01 AG012101-15 · United States
NIA NIH HHS · AG13616 · United States
NIA NIH HHS · AG08051 · United States
NIA NIH HHS · R01 AG022374-04 · United States
NIA NIH HHS · AG12101 · United States
External Links
PubMed source DOI: 10.1016/j.neurobiolaging.2006.12.008 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2